Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.61 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.61 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.61 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GABRP | O00591 | 1/20 | 0.50 |
| ▸ | GABRD | O14764 | 1/20 | 0.50 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.50 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4841451 | 1.00 | CYP1A2 (0.61) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL4841462 | 1.00 | CYP1A2 (0.61) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL17743465 | 0.98 | CYP1A2 (0.59) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL7976406 | 0.85 | ALOX15 (0.45) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL7976410 | 0.85 | ALOX15 (0.45) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL21987337 | 0.81 | CYP1A2 (0.41) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL10639687 | 0.81 | CYP1A2 (0.41) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL6519671 | 0.81 | CYP1A2 (0.46) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL6520647 | 0.81 | CYP1A2 (0.46) | CYP1A2ALOX15CYP2C19CYP2D6SLC1A2 | |
| SCHEMBL1527305 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-7105539-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-09-12 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| EP-1572645-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | Enobia Pharma Inc. (CA) | 2005-09-14 | — | — | EP | disclosed |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | BIOMEP INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004050620-A2 | DERIVATIVES OF SUCCINIC AND GLUTARIC ACIDS AND ANALOGS THEREOF USEFUL AS INHIBITORS OF PHEX | ENOBIA PHARMA (CA) | 2004-06-17 | — | — | WO | disclosed |
| US-5610165-A | N-acylpiperidine tachykinin antagonists | MERCK & CO., INC. (US) | 1997-03-11 | — | — | US | disclosed |
| WO-1995022525-A1 | N-ACYLPIPERIDINE TACHYKININ ANTAGONISTS | MERCK & CO., INC. (US) | 1995-08-24 | — | — | WO | disclosed |
| EP-0573467-B1 | NEUROLEPTIC PERHYDRO-1H-PYRIDO 1,2-a]PYRAZINES | PFIZER (US) | 1995-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | CYP1A2 1770/4885ALOX15 2098/4885CYP2C19 888/4885 |
| US-20040186301-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, PGD | CYP1A2 1550/4885ALOX15 2056/4885CYP2C19 790/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | CYP1A2 1488/4885ALOX15 1969/4885CYP2C19 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.